SLC5A2 and type 2 diabetes mellitus: In those with T2D, a recent meta-analysis (including EMPA-REG Outcome [2], CANVAS Program [1], DECLARE-TIMI58 [3] and CREDENCE [4]) reported an overall significant reduction in MACE in those treated with SGLT2 inhibition as compared to placebo (HR 0.88, 95% CI 0.82 to 0.94).